Status of, and strategies for improving, adherence to HCC screening and surveillance

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.2126225651787
   PubMed Web of Science ®Google Scholar
• Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151–171. doi:10.1016/j.jhep.2018.09.01430266282
   PubMed Web of Science ®Google Scholar
• Bertuccio P, Turati F, Carioli G, et al. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol. 2017;67(2):302–309. doi:10.1016/j.jhep.2017.03.01128336466
   PubMed Web of Science ®Google Scholar
• Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329–338. doi:10.1055/s-2007-100712210518312
   PubMed Web of Science ®Google Scholar
• Taouli B, Goh JS, Lu Y, et al. Growth rate of hepatocellular carcinoma: evaluation with serial computed tomography or magnetic resonance imaging. J Comput Assist Tomogr. 2005;29(4):425–429.16012295
   PubMed Web of Science ®Google Scholar
• Barbara L, Benzi G, Gaiani S, et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology. 1992;16(1):132–137.1352268
   PubMed Web of Science ®Google Scholar
• Sheu JC, Sung JL, Chen DS, et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology. 1985;89(2):259–266.2408960
   PubMed Web of Science ®Google Scholar
• An C, Choi YA, Choi D, et al. Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease. Clin Mol Hepatol. 2015;21(3):279–286. doi:10.3350/cmh.2015.21.3.27926523271
   PubMedGoogle Scholar
• European Association for the Study of the Liver.European Association for the Study of the Liver.EASL Clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi:10.1016/j.jhep.2018.03.01929628281
   PubMed Web of Science ®Google Scholar
• Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–750. doi:10.1002/hep.2991329624699
   PubMed Web of Science ®Google Scholar
• Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4):317–370. doi:10.1007/s12072-017-9799-928620797
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Can Liver Cancer Be Found Early? Vol. 2018 Atlanta, GA: American Cancer Society; 2016.
   Google Scholar
• National Cancer Institute. Liver (hepatocellular) cancer screening—health professional version. Available from: https://www.cancer.gov/types/liver/hp/liver-screening. Accessed 19, 2018.
   Google Scholar
• Mourad A, Deuffic-Burban S, Ganne-Carrié N, et al. Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: a modeling approach. Hepatology. 2014;59(4):1471–1481. doi:10.1002/hep.2694424677195
   PubMed Web of Science ®Google Scholar
• Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, El-Serag HB. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology. 2010;52(1):132–141. doi:10.1002/hep.2361520578139
   PubMed Web of Science ®Google Scholar
• Davila JA, Henderson L, Kramer JR, et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med. 2011;154(2):85–93.21242365
   PubMed Web of Science ®Google Scholar
• Schutte K, Bornschein J, Kahl S, et al. Delayed diagnosis of HCC with chronic alcoholic liver disease. Liver Cancer. 2012;1(3–4):257–266. doi:10.1159/00034384024159590
   PubMed Web of Science ®Google Scholar
• Edenvik P, Davidsdottir L, Oksanen A, Isaksson B, Hultcrantz R, Stal P. Application of hepatocellular carcinoma surveillance in a European setting. What can we learn from clinical practice? Liver Int. 2015;35(7):1862–1871. doi:10.1111/liv.1276425524812
   PubMed Web of Science ®Google Scholar
• Zhao C, Jin M, Le RH, et al. Poor adherence to hepatocellular carcinoma surveillance: a systematic review and meta-analysis of a complex issue. Liver Int. 2018;38(3):503–514. doi:10.1111/liv.1355528834146
   PubMed Web of Science ®Google Scholar
• Kang JY, Lee TP, Yap I, Lun KC. Analysis of cost-effectiveness of different strategies for hepatocellular carcinoma screening in hepatitis B virus carriers. J Gastroenterol Hepatol. 1992;7(5):463–482.1382657
   PubMed Web of Science ®Google Scholar
• Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol. 2003;98(3):679–690.12650806
   PubMed Web of Science ®Google Scholar
• Lin OS, Keeffe EB, Sanders GD, Owens DK. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther. 2004;19(11):1159–1726. doi:10.1111/j.1365-2036.2004.01963.x15153169
   PubMed Web of Science ®Google Scholar
• Andersson KL, Salomon JA, Goldie SJ, Chung RT. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2008;6(12):1418–1424. doi:10.1016/j.cgh.2008.08.00518848905
   PubMed Web of Science ®Google Scholar
• Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with child-pugh class A cirrhosis. Am J Med. 1996;101(4):422–434. doi:10.1016/S0002-9343(96)00197-08873514
   PubMed Web of Science ®Google Scholar
• Patel D, Terrault NA, Yao FY, Bass NM, Ladabaum U. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol. 2005;3(1):75–84.15645408
   PubMed Web of Science ®Google Scholar
• Nouso K, Tanaka H, Uematsu S, et al. Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances. J Gastroenterol Hepatol. 2008;23(3):437–444. doi:10.1111/j.1440-1746.2007.05054.x17683496
   PubMed Web of Science ®Google Scholar
• Cucchetti A, Trevisani F, Cescon M, et al. Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian liver cancer population. J Hepatol. 2012;56(5):1089–1096. doi:10.1016/j.jhep.2011.11.02222245900
   PubMed Web of Science ®Google Scholar
• Thompson Coon J, Rogers G, Hewson P, et al. Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis. Br J Cancer. 2008;98(7):1166–1175. doi:10.1038/sj.bjc.660430118382459
   PubMed Web of Science ®Google Scholar
• Cadier B, Bulsei J, Nahon P; for ANRS CO12 CirVir and CHANGH groups, et al. Early detection and curative treatment of hepatocellular carcinoma: a cost-effectiveness analysis in France and in the United States. Hepatology. 2017;65(4):1237–1248. doi:10.1002/hep.28961.28176349
   PubMed Web of Science ®Google Scholar
• Nowak A, Giger RS, Krayenbuehl PA. Higher age at diagnosis of hemochromatosis is the strongest predictor of the occurrence of hepatocellular carcinoma in the Swiss hemochromatosis cohort: a prospective longitudinal observational study. Medicine (Baltimore). 2018;97(42):e12886. doi:10.1097/MD.000000000001288630335010
   PubMed Web of Science ®Google Scholar
• Cavazza A, Caballería L, Floreani A, et al. Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers. Hepatology. 2009;50(4):1162–1168. doi:10.1002/hep.2309519585656
   PubMed Web of Science ®Google Scholar
• Ganne-Carrié N, Chaffaut C, Bourcier V; for CIRRAL Group, et al. Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis. J Hepatol. 2018;69(6):1274–1283. doi:10.1016/j.jhep.2018.07.022.30092234
   PubMed Web of Science ®Google Scholar
• D’Amico G, Bataller R. Need for surveillance of hepatocellular carcinoma in patients with alcoholic cirrhosis. J Hepatol. 2018;69(6):1219–1220. doi:10.1016/j.jhep.2018.09.02730318321
   PubMed Web of Science ®Google Scholar
• Kanwal F, Kramer JR, Mapakshi S, et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology. 2018;155(6):1828–1837. doi:10.1053/j.gastro.2018.08.02430144434
   PubMed Web of Science ®Google Scholar
• Kolly P, Dufour JF. Surveillance for hepatocellular carcinoma in patients with NASH. Diagnostics. 2016;6(2):E22. doi:10.3390/diagnostics602002227338480
   PubMed Web of Science ®Google Scholar
• Sherman M. Surveillance for hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2014;28(5):783–793. doi:10.1016/j.bpg.2014.08.00825260308
   PubMed Web of Science ®Google Scholar
• Wong VW-S, Janssen HLA. Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection? J Hepatol. 2015;63(3):722–732. doi:10.1016/j.jhep.2015.05.01926026875
   PubMed Web of Science ®Google Scholar
• Diaz-Gonzalez A, Forner A. Surveillance for hepatocellular carcinoma. Best Pract Res Clin Gastroenterol.2016;30(6):1001–1010. doi:10.1016/j.bpg.2016.04.00727938779
   PubMed Web of Science ®Google Scholar
• Chen CJ, Yang HI, Iloeje UH. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology. 2009;49(5 suppl):S72–S84. doi:10.1002/hep.2288419399801
   PubMed Web of Science ®Google Scholar
• Yang HI, Yuen MF, Chan HL, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH B): development and validation of a predictive score. Lancet Oncol. 2011;12(6):568–574. doi:10.1016/S1470-2045(11)70150-421497551
   PubMed Web of Science ®Google Scholar
• Lok AS, Seeff LB, Morgan TR, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009;136(1):138–148. doi:10.1053/j.gastro.2008.09.01418848939
   PubMed Web of Science ®Google Scholar
• Masuzaki R, Tateishi R, Yoshida H, et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology. 2009;49(6):1954–1961. doi:10.1002/hep.2287019434742
   PubMed Web of Science ®Google Scholar
• Kim MN, Kim SU, Kim BK, et al. Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis. Hepatology. 2015;61(6):1851–1859. doi:10.1002/hep.2773525643638
   PubMed Web of Science ®Google Scholar
• Singal AG, Conjeevaram HS, Volk ML, et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev. 2012;21(5):793–799. doi:10.1158/1055-9965.EPI-11-100522374994
   PubMed Web of Science ®Google Scholar
• Del Poggio P, Olmi S, Ciccarese F, et al. Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2014;12(11):1927–1933. doi:10.1016/j.cgh.2014.02.02524582947
   PubMed Web of Science ®Google Scholar
• Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology. 2018;154(6):1706–1718. doi:10.1053/j.gastro.2018.01.06429425931
   PubMed Web of Science ®Google Scholar
• Cucchetti A, Trevisani F, Pecorelli A, et al. Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma. J Hepatol. 2014;61(2):333–341. doi:10.1016/j.jhep.2014.03.03724717522
   PubMed Web of Science ®Google Scholar
• Serper M, Taddei TH, Mehta R, et al. Association of provider specialty and multidisciplinary care with hepatocellular carcinoma treatment and mortality. Gastroenterology. 2017;152(8):1954–1964. doi:10.1053/j.gastro.2017.02.04028283421
   PubMed Web of Science ®Google Scholar
• Borzio M, Dionigi E, Rossini A, et al. Trend of improving prognosis of hepatocellular carcinoma in clinical practice. An Italian In-Field Experience Dig Dis Sci. 2015;60(5):1465–1473. doi:10.1007/s10620-014-3427-525399329
   PubMed Web of Science ®Google Scholar
• Trevisani F, Santi V, Gramenzi A, et al. Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis? Am J Gastroenterol. 2007;102(11):2448–2457. doi:10.1111/j.1572-0241.2007.01395.x17617210
   PubMed Web of Science ®Google Scholar
• Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2018 [Epub ahead of print]. doi:10.1002/ijc.31937
   Web of Science ®Google Scholar
• Moon AM, Weiss NS, Beste LA, et al. No association between screening for hepatocellular carcinoma and reduced cancer-related mortality in patients with cirrhosis. Gastroenterology.2018;155(4):1128–1139. doi:10.1053/j.gastro.2018.06.07929981779
   PubMed Web of Science ®Google Scholar
• Kelley MJ. Surveillance for hepatocellular carcinoma. Ann Intern Med. 2011;155(4):274 author reply 275. doi:10.7326/0003-4819-155-4-201108160-00016
   Web of Science ®Google Scholar
• Lederle FA, Pocha C. Screening for liver cancer: the rush to judgment. Ann Intern Med. 2012;156(5):387–389. doi:10.7326/0003-4819-156-3-201202070-0000622393134
   PubMed Web of Science ®Google Scholar
• Atiq O, Tiro J, Yopp AC, et al. An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. Hepatology. 2017;65(4):1196–1205. doi:10.1002/hep.2889527775821
   PubMed Web of Science ®Google Scholar
• Konerman MA, Verma A, Zhao B, Singal AG, Lok AS, Parikh ND. Frequency and outcomes of abnormal imaging in patients with cirrhosis enrolled in a hepatocellular Carcinoma surveillance program. Liver Transpl. 2019;25(3):369–379. doi:10.1002/lt.2539830582779
   PubMed Web of Science ®Google Scholar
• Costentin CE, Layese R, Bourcier V, et al. Compliance with hepatocellular carcinoma surveillance guidelines associated with increased lead-time adjusted survival of patients with compensated viral cirrhosis: a multi-center cohort study. Gastroenterology. 2018;155(2):431–442. doi:10.1053/j.gastro.2018.04.02729729258
   PubMed Web of Science ®Google Scholar
• Stravitz RT, Heuman DM, Chand N, et al. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med. 2008;121(12):119–126. doi:10.1016/j.amjmed.2007.09.02018261500
   PubMed Web of Science ®Google Scholar
• Singal AG, Yopp A, Gupta S, et al. Failure rates in the hepatocellular carcinoma surveillance process. Cancer Prev Res. 2012;5(9):1124–1130. doi:10.1158/1940-6207.CAPR-12-0046
   PubMed Web of Science ®Google Scholar
• Walker M, El-Serag HB, Sada Y, et al. Cirrhosis is under-recognised in patients subsequently diagnosed with hepatocellular cancer. Aliment Pharmacol Ther. 2016;43(5):621–630. doi:10.1111/apt.1350526784271
   PubMed Web of Science ®Google Scholar
• Kramer JR, Davila JA, Miller ED, Richardson P, Giordano TP, El-Serag HB. The validity of viral hepatitis and chronic liver disease diagnoses in veterans affairs administrative databases. Aliment Pharmacol Ther. 2008;27(3):274–282. doi:10.1111/j.1365-2036.2007.03572.x17996017
   PubMed Web of Science ®Google Scholar
• Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011;53(3):726–736. doi:10.1002/hep.2410521319189
   PubMed Web of Science ®Google Scholar
• Nehra M, Ma Y, Clark CB, Amarasingham R, Rockey DC, Singal AG. Use of administrative claims data for identifying patients with cirrhosis. J Clin Gastroenterol. 2013;47(5):e50–e54. doi:10.1097/MCG.0b013e3182688d2f23090041
   PubMed Web of Science ®Google Scholar
• Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Ward JW. Hepatitis C virus testing of persons born during 1945–1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med. 2012;157(11):817–822. doi:10.7326/0003-4819-157-9-201211060-0052922910836
   PubMed Web of Science ®Google Scholar
• Moyer VA. U.S. preventive services task force. Screening for hepatitis C virus infection in adults: U.S. preventive services task force recommendation statement. Ann Intern Med. 2013;159(5):349–357. doi:10.7326/0003-4819-159-5-201309030-0067223798026
   PubMed Web of Science ®Google Scholar
• Deuffic-Burban S, Huneau A, Verleene A, et al. Assessing the cost-effectiveness of hepatitis C screening strategies in France. J Hepatol. 2018;69(4):785–792. doi:10.1016/j.jhep.2018.05.02730227916
   PubMed Web of Science ®Google Scholar
• Rein DB, Wittenborn JS, Dougherty MC. The cost-effectiveness of a one-time hepatitis C virus antibody test followed by treatment for all Americans ages 18 and older as compared to current testing recommendations in the United States. J Hepatol. 2017;66:S405. doi:10.1016/S0168-8278(17)31168-6
   Web of Science ®Google Scholar
• Barocas JA, Tasillo A, Eftekhari Yazdi G, et al. Population level outcomes and cost-effectiveness of expanding the recommendation for age-based hepatitis C testing in the United States. Clin Infect Dis. 2018;67(4):549–556. doi:10.1093/cid/ciy09829420742
   PubMed Web of Science ®Google Scholar
• Leung C, Yeoh SW, Patrick D, et al. Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease. World J Gastroenterol. 2015;21(4):1189–1196. doi:10.3748/wjg.v21.i10.293725632192
   PubMed Web of Science ®Google Scholar
• Giannini EG, Marabotto E, Savarino V, Italian Liver Cancer (ITALICA) Group, et al.. Hepatocellular carcinoma in patients with cryptogenic cirrhosis. Clin Gastroenterol Hepatol. 2009;7(5):580–585.19418607
   PubMed Web of Science ®Google Scholar
• Piscaglia F, Svegliati-Baroni G, Barchetti A; HCC-NAFLD Italian Study Group, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. Hepatology. 2016;63(3):827–838. doi:10.1002/hep.28368.26599351
   PubMed Web of Science ®Google Scholar
• Dalton-Fitzgerald E, Tiro J, Kandunoori P, Halm EA, Yopp A, Singal AG. Practice patterns and attitudes of primary care providers and barriers to surveillance of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2015;13(4):791–798. doi:10.1016/j.cgh.2014.06.03125019694
   PubMed Web of Science ®Google Scholar
• Singal AG, Li X, Tiro J, et al. Racial, social, and clinical determinants of hepatocellular carcinoma surveillance. Am J Med. 2015;128(1):90.e1–90.e7. doi:10.1016/j.amjmed.2014.07.027
   Web of Science ®Google Scholar
• Beste LA, Ioannou GN, Yang Y, Chang MF, Ross D, Dominitz JA. Improved surveillance for hepatocellular carcinoma with a primary care-oriented clinical reminder. Clin Gastroenterol Hepatol. 2015;13(1):172–179. doi:10.1016/j.cgh.2014.04.03324813175
   PubMed Web of Science ®Google Scholar
• Del Poggio P, Olmi S, Ciccarese F, et al. A training program for primary care physicians improves the effectiveness of ultrasound surveillance of hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2015;27(9):1103–1108. doi:10.1097/MEG.000000000000040426049705
   PubMed Web of Science ®Google Scholar
• Farvardin S, Patel J, Khambaty M, et al. Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis. Hepatology. 2017;65(3):875–884. doi:10.1002/hep.2877027531684
   PubMed Web of Science ®Google Scholar
• Zhao C, Nguyen MH. Hepatocellular carcinoma screening and surveillance: practice guidelines and real-life practice. J Clin Gastroenterol. 2016;50(2):120–133. doi:10.1097/MCG.000000000000044626583266
   PubMed Web of Science ®Google Scholar
• Wong CR, Garcia RT, Trinh HN, et al. Adherence to screening for hepatocellular carcinoma among patients with cirrhosis or chronic hepatitis B in a community setting. Dig Dis Sci. 2009;54(12):2712–2721. doi:10.1007/s10620-009-1015-x19876735
   PubMed Web of Science ®Google Scholar
• Sarkar M, Shvachko VA, Ready JB, et al. Characteristics and management of patients with chronic hepatitis B in an integrated care setting. Dig Dis Sci. 2014;59(9):2100–2108. doi:10.1007/s10620-014-3142-224728968
   PubMed Web of Science ®Google Scholar
• Ly CL, Wong LL. Ethnicity as a predictive factor for hepatocellular carcinoma screening among patients in Hawaii. Ethn Dis. 2014;24(3):376–381.25065082
   PubMed Web of Science ®Google Scholar
• Palmer LB, Kappelman MD, Sandler RS, Hayashi PH. Surveillance for hepatocellular carcinoma in a Medicaid cirrhotic population. J Clin Gastroenterol. 2013;47(8):713–718. doi:10.1097/MCG.0b013e318286fd9723442840
   PubMed Web of Science ®Google Scholar
• Tran SA, Le A, Zhao C, et al. Rate of hepatocellular carcinoma surveillance remains low for a large, real-life cohort of patients with hepatitis C cirrhosis. BMJ Open Gastroenterol. 2018;5(1):e000192. doi:10.1136/bmjgast-2017-000192
   PubMed Web of Science ®Google Scholar
• Singal AG, Tiro JA, Murphy CC, et al. Mailed outreach invitations significantly improve hcc surveillance rates in patients with cirrhosis: a randomized clinical trial. Hepatology. 2019;69(1):121–130. doi:10.1002/hep.3012930070379
   PubMed Web of Science ®Google Scholar
• Pocha C, Dieperink E, McMaken KA, Knott A, Thuras P, Ho SB. Surveillance for hepatocellular cancer with ultrasonography vs computed tomography—a randomised study. Aliment Pharmacol Ther. 2013;38(3):303–312. doi:10.1111/apt.2013.38.issue-323750991
   PubMed Web of Science ®Google Scholar
• Kim SY, An J, Lim YS, et al. MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma. JAMA Oncol. 2017;3(4):456–463. doi:10.1001/jamaoncol.2016.314727657493
   PubMed Web of Science ®Google Scholar
• Marks RM, Ryan A, Heba ER, et al. Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance. AJR Am J Roentgenol. 2015;204(3):527–535. doi:10.2214/AJR.14.1298625714281
   PubMed Web of Science ®Google Scholar
• Besa C, Lewis S, Pandharipande PV, et al. Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion- weighted and T1-weighted imaging at the delayed phase post gadoxetic acid.Abdom Radiol. 2017;42(1):179–190. doi:10.1007/s00261-017-1139-y
   PubMed Web of Science ®Google Scholar
• Tillman BG, Gorman JD, Hru JM, et al. Diagnostic per-lesion performance of a simulated gadoxetate disodium-enhanced abbreviated MRI protocol for hepatocellular carcinoma screening. Clin Radiol. 2018;73(5):485–493. doi:10.1016/j.crad.2017.11.01329246586
   PubMed Web of Science ®Google Scholar
• Lee JY, Huo EJ, Weinstein S, et al. Evaluation of an abbreviated screening MRI protocol for patients at risk for hepatocellular carcinoma. Abdom Radiol. 2018;43(7):1627–1633. doi:10.1007/s00261-017-1339-5
   Web of Science ®Google Scholar
• Goossens N, Singal AG, King LY, et al. Cost-effectiveness of risk score-stratified hepatocellular carcinoma screening in patients with cirrhosis. Clin Transl Gastroenterol. 2017;8(6):e101. doi:10.1038/ctg.2017.2628640287
   PubMed Web of Science ®Google Scholar
• Lee E, Edward S, Singal AG, Lavieri MS, Volk M. Improving screening for hepatocellular carcinoma by incorporating data on levels of alpha-fetoprotein, over time. Clin Gastroenterol Hepatol. 2013;11(4):437–440. doi:10.1016/j.cgh.2012.11.02923247324
   PubMed Web of Science ®Google Scholar
• Tayob N, Lok AS, Do KA, Feng Z. Improved detection of hepatocellular carcinoma by using a longitudinal alpha-fetoprotein screening algorithm. Clin Gastroenterol Hepatol. 2016;14(3):469–475. doi:10.1016/j.cgh.2015.07.04926260109
   PubMed Web of Science ®Google Scholar
• Lok AS, Sterling RK, Everhart JE, et al. Des-gamma-carboxy prothrombin and alphafetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology.2010;138(2)::493–502. doi:10.1053/j.gastro.2009.08.053
   Web of Science ®Google Scholar
• Marrero JA, Feng Z, Wang Y, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology.2009;137(1):110–118. doi:10.1053/j.gastro.2009.04.00519362088
   PubMed Web of Science ®Google Scholar
• Aoyagi Y, Isemura M, Suzuki Y, et al. Fucosylated alpha-fetoprotein as marker of early hepatocellular carcinoma. Lancet. 1985;2(8468):1353–1354. doi:10.1016/S0140-6736(85)92643-1
   Web of Science ®Google Scholar
• Wang M, Sanda M, Comunale MA, et al. Changes in the glycosylation of kininogen and the development of a Kininogen-based algorithm for the early detection of HCC. Cancer Epidemiol Biomarkers Prev. 2017;26(5):795–803. doi:10.1158/1055-9965.EPI-16-097428223431
   PubMed Web of Science ®Google Scholar
• Mao Y, Yang H, Xu H, et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut. 2010;59(12):1687–1693. doi:10.1136/gut.2010.21491620876776
   PubMed Web of Science ®Google Scholar
• Shang S, Plymoth A, Ge S, et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology. 2012;55(2):483–490. doi:10.1002/hep.2470321953299
   PubMed Web of Science ®Google Scholar
• Lin X-J, Chong Y, Guo Z-W, et al. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. Lancet Oncol. 2015;16(7):804–815. doi:10.1016/S1470-2045(15)00048-026088272
   PubMed Web of Science ®Google Scholar
• Li B, Li B, Guo T, et al. Artificial neural network models for early diagnosis of hepatocellular carcinoma using serum levels of α-fetoprotein, α-fetoprotein-L3, des-γ-carboxy prothrombin, and Golgi protein 73. Oncotarget. 2017;8(46):80521–80530. doi:10.18632/oncotarget.1929829113322
   PubMedGoogle Scholar
• Choi J, Kim GA, Han S, Lee W, Chun S, Lim YS. Longitudinal assessment of three serum biomarkers to detect very early stage hepatocellular carcinoma. Hepatology. 2019;69(5):1983–1994. doi:10.1002/hep.3023330153338
   PubMed Web of Science ®Google Scholar
• Yang JD, Patel T. Early detection of hepatocellular carcinoma: expanding the utility of circulating tumor markers. Hepatology. 2019;69(5):1855–1857. doi:10.1002/hep.3046830556586
   PubMed Web of Science ®Google Scholar
• Yuen MF, Tanaka D, Fong YT, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatology. 2009;50(1):80–88. doi:10.1016/j.jhep.2008.07.023
   PubMed Web of Science ®Google Scholar
• Wong VW, Chan SL, Mo F, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol. 2010;28(10):1660–1665. doi:10.1200/JCO.2009.26.267520194845
   PubMed Web of Science ®Google Scholar
• Papatheorodidis G, Dalekos G, Sypsa V, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasian with chronic hepatitis B on 5-year antiviral therapy. J Hepatol. 2016;64(4):800–806. doi:10.1016/j.jhep.2015.11.03526678008
   PubMed Web of Science ®Google Scholar
• Lee HW, Yoo EJ, Kim BK, et al. Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy. Am J Gastroenterol. 2014;109:1241–2499. doi:10.1038/ajg.2014.15724957159
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim YD, Lee M, et al. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy. J Hepatol. 2018;69(5):1066–1073. doi:10.1016/j.jhep.2018.07.01830075230
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Pirrie SJ, Cox TF, et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol Biomarkers Prev. 2014;23(1):144–153. doi:10.1158/1055-9965.EPI-13-087024220911
   PubMed Web of Science ®Google Scholar
• Best J, Bilgi H, Heider D, et al. The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma. Z Gastroenterol. 2016;54(12):1296–1305. doi:10.1055/s-0042-11952927936479
   PubMed Web of Science ®Google Scholar
• Yang JD, Addissie BD, Mara KC, et al. GALAD score for hepatocellular carcinoma detection in comparison to liver ultrasound and proposal of GALADUS score. Cancer Epidemiol Biomarkers Prev. 2018:cebp.0281.2018 [Epub ahead of print]. doi:10.1158/1055-9965.EPI-18-0281
   Web of Science ®Google Scholar
• Wang M, Devarajan K, Singal AG, et al. The Doylestown algorithm: a test to improve the performance of AFP in the detection of hepatocellular carcinoma. Cancer Prev Res (Phila). 2016;9(2):172–179. doi:10.1158/1940-6207.CAPR-15-018626712941
   PubMed Web of Science ®Google Scholar
• Goossens N, Sun X, Hoshida Y. Molecular classification of hepatocellular carcinoma: potential therapeutic implications. Hepat Oncol. 2015;2(4):371–379. doi:10.2217/hep.15.2626617981
   PubMedGoogle Scholar
• Goossens N, Bian CB, Hoshida Y. Tailored algorithms for hepatocellular carcinoma surveillance: is one-size-fits-all strategy outdated? Curr Hepatol Rep. 2017;16(1):64–71. doi:10.1007/s11901-017-0336-z28337405
   PubMedGoogle Scholar
• Tanabe KK, Lemoine A, Finkelstein DM, et al. Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA. 2008;299(1):53–60. doi:10.1001/jama.2007.6518167406
   PubMed Web of Science ®Google Scholar
• Abu Dayyeh BK, Yang M, Fuchs BC, et al. A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology.2011;141(1):141–149. doi:10.1053/j.gastro.2011.03.04521440548
   PubMed Web of Science ®Google Scholar
• Hoshida Y, Villanueva A, Sangiovanni A, et al. Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology. 2013;144(5):1024–1030. doi:10.1053/j.gastro.2013.01.02123333348
   PubMed Web of Science ®Google Scholar
• King LY, Canasto-Chibuque C, Johnson KB, et al. A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Gut. 2015;64(8):1296–1302. doi:10.1136/gutjnl-2014-30786225143343
   PubMed Web of Science ®Google Scholar